Want to see JP:4553 full AI Analyst Report?
4553 Stock Chart & Stats
¥3620.00
-¥90.00(-2.71%)
At close: 4:00 PM EST
¥3620.00
-¥90.00(-2.71%)
Day’s Range― - ―
52-Week Range¥2,764.00 - ¥4,490.00
Previous CloseN/A
Volume116.60K
Average Volume (3M)91.83K
Market Cap
¥173.24B
Enterprise Value¥375.50B
Total Cash (Recent Filing)¥42.23B
Total Debt (Recent Filing)¥229.93B
Price to Earnings (P/E)21.0
Beta0.55
Next Earnings
Nov 11, 2026EPS Estimate
101.18Next Dividend Ex-DateN/A
Dividend Yield2.27%
Share Statistics
EPS (TTM)167.96
Shares Outstanding51,516,000
10 Day Avg. Volume108,900
30 Day Avg. Volume91,826
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)1.11
Price to Sales (P/S)0.72
P/FCF Ratio24.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)469.88
Revenue Forecast (FY)¥306.59B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthContinued top-line expansion indicates that Towa is still increasing sales despite pressure on earnings. Sustained revenue growth supports portfolio scale, helps absorb fixed manufacturing costs, and provides a foundation for restoring profitability as operating execution improves.
Stable Gross MarginA stable gross margin suggests that core pricing and production economics have remained resilient while revenue expanded. This provides an important base for future earnings recovery, because improved cost control or operating efficiency could flow through from a relatively consistent gross-profit structure.
Broad Generic PortfolioA broad portfolio across multiple therapeutic areas gives Towa diversified product exposure within Japan's generic-drug market. The model combines development, manufacturing, and commercialization, supporting recurring prescription sales and reducing reliance on a single medicine or treatment category.
Bears Say
Profitability CompressionSharp deterioration in net and EBIT margins means revenue growth is currently producing much less earnings than in prior periods. If this persists, weaker internal profit generation could constrain reinvestment, reduce returns on the business, and make recovery dependent on successful cost improvement.
Elevated LeverageHigher debt relative to equity increases the financial burden at a time when profitability and ROE have weakened. This combination reduces balance-sheet flexibility, leaves less room to absorb operating setbacks, and may limit the company's ability to fund growth or return capital while earnings remain under pressure.
Weak Cash ConversionThin and volatile free cash flow indicates that accounting earnings are not consistently translating into surplus cash after investment needs. Weak conversion can restrict internally funded expansion, make cash returns less dependable, and increase the importance of disciplined spending and working-capital execution.
Towa Pharmaceutical Co News
4553 FAQ
What was Towa Pharmaceutical Co Ltd’s price range in the past 12 months?
Towa Pharmaceutical Co Ltd lowest stock price was ¥2764.00 and its highest was ¥4490.00 in the past 12 months.
What is Towa Pharmaceutical Co Ltd’s market cap?
Towa Pharmaceutical Co Ltd’s market cap is ¥173.24B.
When is Towa Pharmaceutical Co Ltd’s upcoming earnings report date?
Towa Pharmaceutical Co Ltd’s upcoming earnings report date is Nov 11, 2026 which is in 11 days.
How were Towa Pharmaceutical Co Ltd’s earnings last quarter?
Towa Pharmaceutical Co Ltd released its earnings results on Aug 06, 2026. The company reported ¥112.36 earnings per share for the quarter.
Is Towa Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Towa Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Towa Pharmaceutical Co Ltd pay dividends?
Towa Pharmaceutical Co Ltd pays a Semiannually dividend of ¥45 which represents an annual dividend yield of 2.27%. See more information on Towa Pharmaceutical Co Ltd dividends here
What is Towa Pharmaceutical Co Ltd’s EPS estimate?
Towa Pharmaceutical Co Ltd’s EPS estimate is 101.18.
How many shares outstanding does Towa Pharmaceutical Co Ltd have?
Towa Pharmaceutical Co Ltd has 51,516,000 shares outstanding.
What happened to Towa Pharmaceutical Co Ltd’s price movement after its last earnings report?
Towa Pharmaceutical Co Ltd reported an EPS of ¥112.36 in its last earnings report. Following the earnings report the stock price went up 2.205%.
Which hedge fund is a major shareholder of Towa Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4553
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Towa Pharmaceutical Co Ltd
Towa Pharmaceutical Co., Ltd., along with its subsidiaries, is actively engaged in the entire pharmaceutical lifecycle within Japan, from researching and developing to manufacturing and marketing prescription medications, active pharmaceutical ingredients, and intermediate compounds. The company's extensive product offerings target critical therapeutic areas, including diabetes, digestive and nervous system disorders, and allergic conditions. Furthermore, their portfolio encompasses vitamins, antibiotics, and oncology treatments. With a comprehensive collection of approximately 700 distinct drug products, Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―